Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Biomarkers in mCRC
NCT01949194Phase 2Unknown
- Sponsor
- Gerald Batist
- Start
- Sep 2013
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Gerald Batist. Primary endpoint: Biomarker (in blood or tissue) that may be predictive of level of response to regorafenib at 4 years. Status: unknown.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01949194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949194.